PBRM1 Deficiency Confers Synthetic Lethality to DNA Repair Inhibitors in Cancer
Roman M Chabanon,Daphné Morel,Thomas Eychenne,Léo Colmet-Daage,Ilirjana Bajrami,Nicolas Dorvault,Marlène Garrido,Cornelia Meisenberg,Andrew Lamb,Carine Ngo,Suzanna R Hopkins,Theodoros I Roumeliotis,Samuel Jouny,Clémence Hénon,Asuka Kawai-Kawachi,Clémence Astier,Asha Konde,Elaine Del Nery,Christophe Massard,Stephen J Pettitt,Raphaël Margueron,Jyoti S Choudhary,Geneviève Almouzni,Jean-Charles Soria,Eric Deutsch,Jessica A Downs,Christopher J Lord,Sophie Postel-Vinay,Roman M. Chabanon,Suzanna R. Hopkins,Theodoros I. Roumeliotis,Stephen J. Pettitt,Jyoti S. Choudhary,Jessica A. Downs,Christopher J. Lord
DOI: https://doi.org/10.1158/0008-5472.CAN-21-0628
IF: 11.2
2021-06-03
Cancer Research
Abstract:Inactivation of Polybromo 1 (PBRM1), a specific subunit of the PBAF chromatin remodeling complex, occurs frequently in cancer, including 40% of clear cell renal cell carcinomas (ccRCC). To identify novel therapeutic approaches to targeting PBRM1-defective cancers, we used a series of orthogonal functional genomic screens that identified PARP and ATR inhibitors as being synthetic lethal with PBRM1 deficiency. The PBRM1/PARP inhibitor synthetic lethality was recapitulated using several clinical PARP inhibitors in a series of in vitro model systems and in vivo in a xenograft model of ccRCC. In the absence of exogenous DNA damage, PBRM1-defective cells exhibited elevated levels of replication stress, micronuclei, and R-loops. PARP inhibitor exposure exacerbated these phenotypes. Quantitative mass spectrometry revealed that multiple R-loop processing factors were downregulated in PBRM1-defective tumor cells. Exogenous expression of the R-loop resolution enzyme RNase H1 reversed the sensitivity of PBRM1-deficient cells to PARP inhibitors, suggesting that excessive levels of R-loops could be a cause of this synthetic lethality. PARP and ATR inhibitors also induced cyclic GMP-AMP synthase/stimulator of interferon genes (cGAS/STING) innate immune signaling in PBRM1-defective tumor cells. Overall, these findings provide the preclinical basis for using PARP inhibitors in PBRM1-defective cancers.Significance:This study demonstrates that PARP and ATR inhibitors are synthetic lethal with the loss of PBRM1, a PBAF-specific subunit, thus providing the rationale for assessing these inhibitors in patients with PBRM1-defective cancer.Graphical http://cancerres.aacrjournals.org/content/canres/81/11/2888/F1.large.jpg.
oncology